KY19382

    TLDR Experimental compound that activates hair-growth signals, tested only in animals

    KY19382 is a research compound that activates Wnt/β-catenin signalling. In laboratory studies it increased hair-growth markers in human dermal papilla cells, lengthened cultured human follicles over 3 days, and caused hair regrowth and new follicle formation in mice (Ryu et al., British Journal of Pharmacology 2021, PMID 33751552; the senior author's company holds the licence). It has never been tested in people and is not approved anywhere. This pathway plays a crucial role in the regulation of hair follicle development and cycling, making it a prime target for interventions aimed at treating alopecia.

    The role of KY19382 in the context of alopecia, hair growth, or hair loss centers around its ability to activate the Wnt/β-catenin signaling pathway. By doing so, it influences various factors critical for hair growth, such as increasing the expression of alkaline phosphatase (ALP) and the proliferation marker PCNA in dermal papilla cells. This activation not only enhances hair length in ex vivo-cultured mouse vibrissa and human hair follicles but also induced hair regrowth and the formation of new hair follicles in mice. On that basis the researchers proposed it as a possible alopecia treatment; no human data exist.

    In mice, KY19382 promoted hair regrowth and hair follicle neogenesis. The same study observed its ability to activate Wnt/β-catenin signaling in both human and rat dermal papilla cells, a key mechanism through which it promotes hair growth. The compound's impact extends to increasing alkaline phosphatase activity, a marker of hair induction, and enhancing both wound-induced hair follicle neogenesis and hair follicle neogenesis in patch assays. Whether any of this applies to people is unknown: a search of ClinicalTrials.gov (September 2026) found no human trials of KY19382. Powders sold online as KY19382 are unregulated research chemicals; their content and purity are unverified, and their safety on human skin has not been studied.

    The community has recognized KY19382 among discussions of upcoming treatments, referencing it alongside other potential options like clascoterone, pyrilutamide, and GT20029. While direct experiences with KY19382 itself are not extensively documented within the community, its mention alongside other investigational treatments indicates an interest and hope in its future application for hair loss.

    Research

    20 / 56 results
    View more "KY19382" in research →

    FAQs

    Community Join

    17 / 17 results

      community Does anyone have experience with KY19382?

       3 upvotes 9 months ago
      KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.

      community Anyone here ever used KY-19382 or another indirubin analogue?

       2 upvotes 1 year ago
      KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.

      community Verteporfin and KY19382 experiment

       80 upvotes 3 weeks ago
      The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.

      community Why was this compound abandoned ?

       1 upvotes 6 months ago
      KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

      community Is there hope for creating new hair follicles?

       6 upvotes 3 weeks ago
      Creating new hair follicles is unlikely in the next 10-20 years, with current treatments focusing on stimulating existing follicles. Experimental treatments like ky19382 are being tested, but reliable solutions are not yet available.

      community Any experiences with Ptd-dbm??

       8 upvotes 4 months ago
      The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

      community Summary of future treatments from 2020

       51 upvotes 1 year ago
      Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.

      community Best, possible, or experimental growth agonists that AREN'T MINOXIDIL.

       4 upvotes 5 years ago
      Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

      community Where to find ethanol for RU powder

       5 upvotes 4 years ago
      The conversation is about finding ethanol in California for mixing with RU58841 for hair loss treatment. Users suggest alternatives like high-proof alcohol from liquor stores or purchasing lab-grade ethanol online.

      community Now That PP405 Hype is Gone What is Everyone Coping with as the Next Cure?

       41 upvotes 1 month ago
      People are discussing various hair loss treatments, including finasteride, minoxidil, RU58841, and new potential treatments like vdphl01, ABS-201, and KX-826. Some express hope in future developments like hair cloning and CRISPR, while others emphasize acceptance and sticking with current treatments.

      community Hair loss transformation 14-18 yrs old

       3 upvotes 1 month ago
      The user shared their hair loss transformation and treatment routine, which includes dutasteride, finasteride, various forms of minoxidil, and other topical treatments. They emphasized consistency in their regimen and offered to answer questions about their experience.

      community Haircafe slams pp405 presentation. Are results really that bad?

       64 upvotes 6 months ago
      PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

       133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.